CAPECITABINE PLUS OXALIPLATIN (CAPOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN STAGE III COLON CANCER: A COST-MINIMIZATION ANALYSIS BASED ON REAL WORLD COSTS IN THE NETHERLANDS

被引：0
|
作者：
van Gils, C. W. M. [1 ]
de Groot, S. [1 ]
Redekop, W. K. [1 ]
Uyl-De Groot, C. A. [1 ]
机构：
[1] Inst Med Techonol Assessment, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1207
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A453 / A453
页数：1
相关论文
共 50 条
  • [21] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
    Rothenberg, M. L.
    Cox, J. V.
    Butts, C.
    Navarro, M.
    Bang, Y. -J.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Laguerre, S.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1720 - 1726
  • [22] Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer
    Lamberti, C
    Sauerbruch, T
    Glasmacher, A
    CANCER TREATMENT REVIEWS, 2005, 31 (08) : 648 - 652
  • [23] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    ANNALS OF ONCOLOGY, 2005, 16 : 283 - 283
  • [24] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis
    Arkenau, H.
    Kubicka, S.
    Greil, R.
    Schmoll, H.
    Seufferlein, T.
    Greaven, U.
    Grothey, A.
    Kretschmar, A.
    Hinke, A.
    Porschen, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 168
  • [25] Cost-minimization analysis of a phase III study of capecitabine plus oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting
    Perrocheau, G.
    Bennouna, J.
    Ducreux, M.
    Hebbar, M.
    Ychou, M.
    Lledo, G.
    Conroy, T.
    Adenis, A.
    Faroux, R.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US
    Aballea, Samuel
    Chancellor, Jeremy V. M.
    Raikou, Maria
    Drummond, Michael F.
    Weinstein, Milton C.
    Jourdan, Sophia
    Bridgewater, John
    CANCER, 2007, 109 (06) : 1082 - 1089
  • [27] Cost-minimization analysis of capecitabine plus oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting
    Perrocheau, G.
    Ducreux, M.
    Hebbar, M.
    Ychou, M.
    Lledo, G.
    Conroy, T.
    Faroux, R.
    Douillard, J. Y.
    Pacull, A.
    VALUE IN HEALTH, 2007, 10 (06) : A233 - A233
  • [28] Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis.
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Seufferlein, T
    Reichardt, P
    Freier, W
    Graeven, U
    Grothey, A
    Porschen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 256S - 256S
  • [29] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
    Dimitrios Pectasides
    Vasilios Karavasilis
    George Papaxoinis
    Georgia Gourgioti
    Thomas Makatsoris
    Georgia Raptou
    Eleni Vrettou
    Joseph Sgouros
    Epaminontas Samantas
    George Basdanis
    Pavlos Papakostas
    Dimitrios Bafaloukos
    Vassiliki Kotoula
    Haralambos P. Kalofonos
    Chrisoula D. Scopa
    George Pentheroudakis
    George Fountzilas
    BMC Cancer, 15
  • [30] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
    Pectasides, Dimitrios
    Karavasilis, Vasilios
    Papaxoinis, George
    Gourgioti, Georgia
    Makatsoris, Thomas
    Raptou, Georgia
    Vrettou, Eleni
    Sgouros, Joseph
    Samantas, Epaminontas
    Basdanis, George
    Papakostas, Pavlos
    Bafaloukos, Dimitrios
    Kotoula, Vassiliki
    Kalofonos, Haralambos P.
    Scopa, Chrisoula D.
    Pentheroudakis, George
    Fountzilas, George
    BMC CANCER, 2015, 15
12345